News Releases

Date Title and Summary View
Oct 08, 2020
Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate
Agreement provides option for European Union Member States   to secure up to 200 million additional doses for a total of up to 400 million doses NEW BRUNSWICK, N.J., Oct. 8, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on
Oct 06, 2020
Oct 01, 2020
Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.
Acquisition broadens Janssen's leadership in autoimmune diseases and provides a major catalyst for sustained growth NEW BRUNSWICK, N.J. , Oct. 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc.
Sep 30, 2020
Sep 30, 2020
Sep 23, 2020
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S NEW BRUNSWICK, N.J. , Sept. 23, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its
Sep 20, 2020
Sep 14, 2020
Sep 14, 2020
Sep 11, 2020
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.